These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 31310505)

  • 21. Multiplexed Quantitative MALDI MS Approach for Assessing Activity and Inhibition of Protein Kinases Based on Postenrichment Dephosphorylation of Phosphopeptides by Metal-Organic Framework-Templated Porous CeO
    Xu H; Liu M; Huang X; Min Q; Zhu JJ
    Anal Chem; 2018 Aug; 90(16):9859-9867. PubMed ID: 30024740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimization of Aminoimidazole Derivatives as Src Family Kinase Inhibitors.
    Francini CM; Musumeci F; Fallacara AL; Botta L; Molinari A; Artusi R; Mennuni L; Angelucci A; Schenone S
    Molecules; 2018 Sep; 23(9):. PubMed ID: 30227617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ion Mobility-Mass Spectrometry Coupled to Droplet Microfluidics for Rapid Protein Structure Analysis and Drug Discovery.
    D'Amico CI; Polasky DA; Steyer DJ; Ruotolo BT; Kennedy RT
    Anal Chem; 2022 Sep; 94(38):13084-13091. PubMed ID: 36098981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RANKL-induced c-Src activation contributes to conventional anti-cancer drug resistance and dasatinib overcomes this resistance in RANK-expressing multiple myeloma cells.
    Mashimo K; Tsubaki M; Takeda T; Asano R; Jinushi M; Imano M; Satou T; Sakaguchi K; Nishida S
    Clin Exp Med; 2019 Feb; 19(1):133-141. PubMed ID: 30291461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dasatinib attenuates overexpression of Src signaling induced by the combination treatment of veliparib plus carboplatin in triple-negative breast cancer.
    Sun Y; Lin X; Aske JC; Ye P; Williams C; Abramovitz M; Leyland-Jones BR
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1241-1256. PubMed ID: 31541266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
    Formisano L; D'Amato V; Servetto A; Brillante S; Raimondo L; Di Mauro C; Marciano R; Orsini RC; Cosconati S; Randazzo A; Parsons SJ; Montuori N; Veneziani BM; De Placido S; Rosa R; Bianco R
    Oncotarget; 2015 Sep; 6(28):26090-103. PubMed ID: 26325669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phosphoproteomics approach to identify candidate kinase inhibitor pathway targets in lymphoma-like primary cell lines.
    Vojvodic M; Hansford LM; Morozova O; Blakely KM; Taylor P; Fathers KE; Moffat J; Marra M; Smith KM; Moran MF; Kaplan DR
    Curr Drug Discov Technol; 2013 Dec; 10(4):283-304. PubMed ID: 23701117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors.
    Li S; Zhao Y; Wang K; Gao Y; Han J; Cui B; Gong P
    Bioorg Med Chem; 2013 Jun; 21(11):2843-55. PubMed ID: 23628470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, Synthesis, and Evaluation of Dasatinib-Amino Acid and Dasatinib-Fatty Acid Conjugates as Protein Tyrosine Kinase Inhibitors.
    Tiwari RK; Brown A; Sadeghiani N; Shirazi AN; Bolton J; Tse A; Verkhivker G; Parang K; Sun G
    ChemMedChem; 2017 Jan; 12(1):86-99. PubMed ID: 27875633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
    Remsing Rix LL; Rix U; Colinge J; Hantschel O; Bennett KL; Stranzl T; Müller A; Baumgartner C; Valent P; Augustin M; Till JH; Superti-Furga G
    Leukemia; 2009 Mar; 23(3):477-85. PubMed ID: 19039322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-Based Design of a Potent and Selective Covalent Inhibitor for SRC Kinase That Targets a P-Loop Cysteine.
    Du G; Rao S; Gurbani D; Henning NJ; Jiang J; Che J; Yang A; Ficarro SB; Marto JA; Aguirre AJ; Sorger PK; Westover KD; Zhang T; Gray NS
    J Med Chem; 2020 Feb; 63(4):1624-1641. PubMed ID: 31935084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of Aminoimidazole and Aminothiazole Derivatives as Src Family Kinase Inhibitors.
    Francini CM; Fallacara AL; Artusi R; Mennuni L; Calgani A; Angelucci A; Schenone S; Botta M
    ChemMedChem; 2015 Dec; 10(12):2027-41. PubMed ID: 26514807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative collision-induced unfolding differentiates model antibody-drug conjugates.
    Tian Y; Lippens JL; Netirojjanakul C; Campuzano IDG; Ruotolo BT
    Protein Sci; 2019 Mar; 28(3):598-608. PubMed ID: 30499138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pharmacological characteristics and clinical outcomes of ponatinib (Iclusig
    Yoshida T; Leen Liew E; Ota M; Nakayama H; Yanagihara Y; Nakamura Y; Seriu T; Kamishohara M
    Nihon Yakurigaku Zasshi; 2017; 150(1):54-61. PubMed ID: 28690276
    [No Abstract]   [Full Text] [Related]  

  • 35. Exquisitely specific bisubstrate inhibitors of c-Src kinase.
    Brandvold KR; Santos SM; Breen ME; Lachacz EJ; Steffey ME; Soellner MB
    ACS Chem Biol; 2015 Jun; 10(6):1387-91. PubMed ID: 25793938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How and when does an anticancer drug leave its binding site?
    Tiwary P; Mondal J; Berne BJ
    Sci Adv; 2017 May; 3(5):e1700014. PubMed ID: 28580424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity.
    Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Hashizume H; Nozu K; Yoshida H; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Baba Y; Nakamura Y
    J Med Chem; 2015 Feb; 58(4):1760-75. PubMed ID: 25625617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The discovery of substituted 4-(3-hydroxyanilino)-quinolines as potent RET kinase inhibitors.
    Graham Robinett R; Freemerman AJ; Skinner MA; Shewchuk L; Lackey K
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5886-93. PubMed ID: 17884497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative structure-activity relationship studies on some nonbenzodiazepine series of compounds acting at the benzodiazepine receptor.
    Gupta SP; Paleti A
    Bioorg Med Chem; 1998 Nov; 6(11):2213-8. PubMed ID: 9881112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insight into ponatinib resistance mechanisms in rhabdomyosarcoma caused by the mutations in FGFR4 tyrosine kinase using molecular modeling strategies.
    Wu C; Chen X; Chen D; Xia Q; Liu Z; Li F; Yan Y; Cai Y
    Int J Biol Macromol; 2019 Aug; 135():294-302. PubMed ID: 31128178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.